You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The investment banking firm forecast Fiscal Year 2021 revenues of $235.6 million, higher than the consensus Wall Street estimate of $178.4 million.
The genetic testing company said its orders for traditional tests have also rebounded and are on track for growth in the second half of 2020.
BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.
New recommendations advise metastatic prostate cancer patients and others with a family history to consider genetic testing.
Genomic data should be easily accessible to patients and their physicians through electronic health record systems with privacy safeguards.
The investment bank gave shares of the Temple City, California-based genetic testing company a buy rating and a $20 price target.
The deal includes integrating an online ordering process for Ambry's genetic tests into Volpara's Aspen Breast software for medical practice management.
Reuters reports federal investigators are looking into PerkinElmer's role in an alleged Medicare fraud, though the firm says it is unaware of any investigation.
Individuals with autism spectrum disorder who were younger or with a more severe condition were more likely to undergo genetic testing, a new analysis has found.
The San Francisco-based firm reported $64.2 million in revenues, up from $40.6 million a year ago and beating the average Wall Street estimate of $59.4 million.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.